Girentuximab-Zr-89（锆89Zr吉伦妥昔单抗）是一种针对碳酸酐酶IX (CAIX)的单克隆抗体，它通过抑制CAI...
通过在智慧芽Bio生物序列数据库——常规搜索中查询Girentuximab-Zr-89（锆89Zr吉伦妥昔单抗）重链序列Se...
89Zr-girentuximab 基本信息 药品名称 Zr-89-girentuximab; Zr-89-TX250; 89Zr-DFO-girentuximab; TLX250-CDx; 89Zr-TLX250; 89Zr-girentuximab; 锆[89Zr]吉伦妥昔单抗; 89Zr-DFO-TFP-GTX; Zircaix 药品类别 创新药; 生物; 抗体; 放射性药物; 偶联药物 靶点 carbonic anhydrase IX (CAIX)...
ZIRCONIUM (89ZR) GIRENTUXIMAB SENVEDOXAM,来源于药化词典-药智数据
Zirconium-89-Girentuximab (89Zr-TLX250) may have utility in the accurate staging of bladder and urothelial cancer, with less renal excretion as compared to FDG, however this has not previously been investigated. ZipUp is an investigator initiated trial. South Metropolitan Health Service WA is ...
GirentuximabImagingPETPurpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT ...
Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of Zr-89-labeled girentuximab positron emission ...
Purpose: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC le...